A phase II clinical trial of the vascular disrupting agent BNC105P as second line chemotherapy for advanced Malignant Pleural Mesothelioma. (Q50798185)
Jump to navigation
Jump to search
scientific article published on 17 June 2013
| Language | Label | Description | Also known as |
|---|---|---|---|
| English | A phase II clinical trial of the vascular disrupting agent BNC105P as second line chemotherapy for advanced Malignant Pleural Mesothelioma. |
scientific article published on 17 June 2013 |
Statements
A phase II clinical trial of the vascular disrupting agent BNC105P as second line chemotherapy for advanced Malignant Pleural Mesothelioma. (English)
1 reference
1 reference
Jenette Creaney
1 reference
Michael J Millward
1 reference
Michael J Byrne
1 reference
Brett Hughes
1 reference
Gabriel Kremmidiotis
1 reference
David C Bibby
1 reference
Annabell F Leske
1 reference
Paul L R Mitchell
1 reference
Nick Pavlakis
1 reference
Martin R Stockler
1 reference
17 June 2013
1 reference
81
1 reference
3
1 reference
422-427
1 reference
Identifiers
1 reference